Timeline
Diaceutics
Diaceutics reports 75% ARR growth in H1 2026 update
Diaceutics returns to profit as adjusted EBITDA rises 80%
More in Medtech & Diagnostics
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.